Stomach cancer showdown: surgery or chemo first?
NCT ID NCT01717924
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at the best way to treat a rare and aggressive stomach cancer called signet ring cell adenocarcinoma. It compares two strategies: starting with surgery or starting with chemotherapy before surgery. About 314 patients will take part to see which approach helps people live longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- chemotherapy (peri-operative)
- What this could lead to
- If it works, this could show that starting with chemotherapy improves survival for people with this rare stomach cancer.
- What could go wrong
- This is a mid-stage trial, so results are not final. The cancer is rare and aggressive, so even the best approach may have limited success.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SIGNET RING CELL GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
General and digestive surgical department, Claude Huriez Hospital, University Hospital
RECRUITINGLille, 59037, France